Involvement of CDA and/or dCK Metabolizing Enzymes in the Response to Azacytidine Treatment of Patients With Hematologic Malignancies

Launched by ASSISTANCE PUBLIQUE HOPITAUX DE MARSEILLE · Mar 19, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the treatment azacytidine works in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The goal is to personalize the dose of azacytidine based on each patient's genetic makeup and how their body processes the medication. Currently, doses are adjusted after patients experience side effects, which can lead to missed opportunities for effective treatment. By understanding each patient's unique genetic factors, the researchers hope to find the right dose of azacytidine before any serious side effects occur, potentially improving treatment outcomes.

To be eligible for this study, patients must be over 18 years old and diagnosed with AML or MDS. They will need to agree to genetic testing to help tailor their treatment. Participants can expect to receive azacytidine as part of their regular treatment while also undergoing monitoring for any side effects, treatment response, and their overall health. This trial aims to create a more personalized approach to treatment that could help patients get the most benefit from azacytidine while minimizing risks.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients over 18 years of age
• • Patients with acute myeloid leukemia
• • Patient with myelodysplastic syndrome
• • Person who has given non-opposition
• • Patient who has signed an authorization to perform a constitutional genetic analysis (in the context of care)
• • Need for effective contraception in patients of childbearing age
• Exclusion Criteria:
• • Failure to obtain non-opposition
• • Adults under guardianship or safeguard of justice
• • Persons deprived of their liberty
• • Patient participating in another research project
• • Pregnancy in progress